Improvements in Glycemic Control in Type 2 Diabetes Patients Switched From Sulfonylurea Coadministered With Metformin to Glyburide-Metformin Tablets
Explore this paper's citation graph
Summary
The results of this study suggest that in type 2 diabetic patients with an A1C >or=8%, switching from coadministration of a sulfonylurea plus metformin to combination glyburide-metformin tablets may provide an improvement in glycemic control in the range of a 1.2 to 1.4 absolute percentage point decrease in A2C.
- Type
- article
- Published
- 2003-05-01
- Cited by
- 34
- References
- 16
- Access
- Open access
- OpenAlex
- https://openalex.org/W61885398
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:38809754
Keywords
Medicine, Metformin, Glycemic, Type 2 diabetes, Sulfonylurea
References
- Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.
- Glycemic Control with Diet, Sulfonylurea, Metformin, or Insulin in Patients with Type 2 Diabetes Mellitus: Progressive Requirement for Multiple Therapies (UKPDS 49)
- Simultaneous glyburide/metformin therapy is superior to component monotherapy as an initial pharmacological treatment for type 2 diabetes
- Glyburide/metformin combination product is safe and efficacious in patients with type 2 diabetes failing sulphonylurea therapy
- The importance of insulin resistance in the pathogenesis of type 2 diabetes mellitus.
- Pharmacokinetics and Pharmacodynamics of Glyburide/Metformin Tablets (Glucovance™) versus Equivalent Doses of Glyburide and Metformin in Patients with Type 2 Diabetes
- Projection of diabetes burden through 2050: impact of changing demography and disease prevalence in the U.S.
- Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study
- Adherence to oral antidiabetic therapy in a managed care organization: a comparison of monotherapy, combination therapy, and fixed-dose combination therapy.
- Racial and ethnic differences in glycemic control of adults with type 2 diabetes.
- Durability of efficacy and long-term safety profile of glyburide/metformin tablets in patients with type 2 diabetes mellitus: an open-label extension study.
- U.K. Prospective Diabetes Study 16: Overview of 6 Years' Therapy of Type II Diabetes: A Progressive Disease
- Standards of Medical Care for Patients With Diabetes Mellitus
Cited by
- Towards Single-Tablet Therapy for Type 2 Diabetes Mellitus
- Glycaemic control and cost analysis when changing from gliclazide co-administered with metformin to pre-combined glibenclamide-metformin tablets in type 2 diabetes mellitus.
- Fixed‐dose combination therapies in the management of hyperglycaemia in Type 2 diabetes: an opportunity to improve adherence and patient care
- Patient adherence to medication requirements for therapy of type 2 diabetes
- AADE Position Statement
- Effect of Glyburide—Metformin Combination Tablet in Patients with Type 2 Diabetes
- New therapies available for the treatment of type 2 diabetes
- Role of sleep duration and quality in the risk and severity of type 2 diabetes mellitus.
- Impact of untreated obstructive sleep apnea on glucose control in type 2 diabetes.
- Combined treatment of tetrahydrocurcumin and chlorogenic acid exerts potential antihyperglycemic effect on streptozotocin-nicotinamide-induced diabetic rats.
- What’s next after metformin? focus on sulphonylurea: add-on or combination therapy
- Glyburide/metformin tablets: a new therapeutic option for the management of Type 2 diabetes
- Combination of glibenclamide–metformin HCl for the treatment of type 2 diabetes mellitus
- Long-term costs and clinical outcomes associated with metformin-glibenclamide combination tablets (Glucovance®) in patients with type 2 diabetes sub-optimally controlled by metformin: a modelling study in the French setting
- Fixed‐dose single tablet antidiabetic combinations
- Glycemic effectiveness and medication adherence with fixed-dose combination or coadministered dual therapy of antihyperglycemic regimens: a meta-analysis
- Adherence to a Fixed-Dose Combination of Rosiglitazone/Glimepiride in Subjects Switching from Monotherapy or Dual Therapy with a Thiazolidinedione and/or a Sulfonylurea
- A review of treatment response in type 2 diabetes: assessing the role of patient heterogeneity
- Adherence to oral antidiabetic agents with pioglitazone and metformin: comparison of fixed-dose combination therapy with monotherapy and loose-dose combination therapy.
- Synergistic interaction between metformin and sulfonylureas on diclofenac-induced antinociception measured using the formalin test in rats.
Related papers
- Pharmacodynamic aspects of two sulphonylurea derivatives glipizide and glibenclamide
- Improved glycaemic control with metformin–glibenclamide combined tablet therapy (Glucovance®) in Type 2 diabetic patients inadequately controlled on metformin
- [A comparison between glibenclamide and glipizide in the treatment of type II diabetes].
- GLIPIZIDE OFFERS IMPROVED GLUCOSE CONTROL FOR DIABETICS.
- The effect on metabolic control of second-generation sulfonylurea drugs in patients with NIDDM after secondary failure to first-generation agents.
- Comparative single-dose kinetics and effects of four sulfonylureas in healthy volunteers.
- Dynamics of sulfonylurea-induced insulin release from the isolated perfused rat pancreas